Clinical Trial: Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
Brief Summary: Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.
Detailed Summary:
Sponsor: Hospices Civils de Lyon
Current Primary Outcome: Periostin rate in serum [ Time Frame: At inclusion ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Periostin rate in serum according to the number of fibrotic bones [ Time Frame: At inclusion ]
- Periostin rate in serum in patients with severe phenotype of the disease [ Time Frame: At inclusion ]
- Periostin rate in serum in patients with Mac Cune Albright syndrome [ Time Frame: At inclusion ]
Original Secondary Outcome: Same as current
Information By: Hospices Civils de Lyon
Dates:
Date Received: August 11, 2016
Date Started: June 2016
Date Completion: June 2018
Last Updated: August 23, 2016
Last Verified: August 2016
